Chinook Therapeutics ( ) - 株価, ニュースと分析Nasdaq:KDNY

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

KDNY 株式概要

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases.

会社概要

KDNY ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

報酬

収益は年間63.8%増加すると予測されています

リスク分析

過去3か月間の株価の変動は非常に激しい

過去1年間で株主の希薄化が進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Chinook Therapeutics, Inc. 競合他社

ADMA Biologics

NasdaqGM:ADMA

US$2.5b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Crinetics Pharmaceuticals

NasdaqGS:CRNX

US$3.6b

Janux Therapeutics

NasdaqGM:JANX

US$2.1b

価格と性能

の歴代最高値、変動、値下がりまとめChinook Therapeutics
過去の株価
現在の株価	US$40.39
52週高値	US$40.51
52週安値	US$18.34
ベータ	0.67
11ヶ月の変化	2.98%
3ヶ月変化	72.68%
1年変化	95.69%
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	173.46%

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

株主還元

	KDNY	US Biotechs	US 市場
7D	0.3%	0.06%	0.1%
1Y	95.7%	9.9%	24.1%

業界別リターン: KDNY過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: KDNY過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。

価格変動

Is KDNY's price volatile compared to industry and market?
KDNY volatility
KDNY Average Weekly Movement	17.1%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

安定した株価: KDNYの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: KDNYの週次ボラティリティは、過去 1 年間で10%から17%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc. 基礎のまとめ

Chinook Therapeutics の収益と売上を時価総額と比較するとどうか。
KDNY 基礎統計学
時価総額	US$2.90b
収益（TTM）	-US$245.65m
売上高(TTM)	US$5.85m

495.8x

P/Sレシオ

-11.8x

PER（株価収益率

KDNY は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
KDNY 損益計算書（TTM）
収益	US$5.85m
売上原価	US$193.72m
売上総利益	-US$187.87m
その他の費用	US$57.79m
収益	-US$245.65m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-3.42
グロス・マージン	-3,211.95%
純利益率	-4,199.93%
有利子負債／自己資本比率	0%

KDNY の長期的なパフォーマンスは？

過去の実績と比較を見る

KDNY 株式概要

報酬

リスク分析

Chinook Therapeutics, Inc. 競合他社

NasdaqGM:ADMA

US$2.5b

NasdaqGS:TPTX

US$3.8b

NasdaqGS:CRNX

US$3.6b

NasdaqGM:JANX

US$2.1b

価格と性能

最新ニュース

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

株主還元

価格変動

会社概要

Chinook Therapeutics, Inc. 基礎のまとめ

495.8x